SHARE

Fior Markets launched a study titled “Bio Pharma Buffer Market by Type(Phosphates, Acetates, TRIS, Others), Application, Regions”,and Global Forecast 2018-2025.

The global bio pharma buffer market is expected to grow from USD 553.51 Million in 2017 to USD 980.78 Million by 2025, at a CAGR of 7.41% during the forecast period from 2018-2025. Increasing demand for biopharmaceuticals such as vaccines, blood, blood components, allergenics, somatic cells, gene therapies, tissues, recombinant therapeutic protein, and living cells used in cell therapy are propelling the global bio pharma buffer market.

DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/386005/request-sample

Type segment is divided into phosphates, acetates, TRIS and others. Phosphate buffer solution is a water-based salt solution containing disodium hydrogen phosphate, sodium chloride and, in some formulations, potassium chloride and potassium dihydrogen phosphate. It is extensively used in the fields of biological research. Whereas TRIS buffer solutions are used to dilute substances used in laboratory experiments due to their isotonic and non-toxic properties.

Pharmaceutical industry segment had a market value of XX.XX million in 2017

Application segment is divided into research institutions, pharmaceutical industry and other. The pharmaceutical industry application segment emerged as the leader in the global bio pharma buffer market with USD 294.41 million revenue in 2017. Factors such as increasing demand for the biopharmaceuticals like vaccines, antibodies, hormones have proved to be the driving factors behind this increased market share.

BROWSE COMPLETE REPORT AND TABLE OF CONTENTS:https://www.fiormarkets.com/report/bio-pharma-buffer-market-by-type-phosphates-acetates-386005.html

Regional Segmentation Analysis:

The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. North America region has a considerable presence of leading pharmaceutical manufacturers and well-developed medical and healthcare sector as well as robust demand for the biopharmaceuticals. Thus North America region led the global bio pharma buffer market with USD 228.82 million revenue in 2017. Based on the factors such as swift development of pharmaceuticals industry coupled with increased government spending on improving the standards of the healthcare facilities and implementation of massive immunization programs, the Asia Pacific region is projected to grow at the highest CAGR of 9.53% over the forecast period.

Although the rising demand for blood and blood plasma for transfusion purposes and ongoing vaccination program against polio, rubella and other such diseases around the world are driving the global bio-pharma buffer market. Factors such as the highly competitive nature of the market as well as concerns related to toxicity of certain buffer solutions are anticipated to hamper the growth of the market over the forecast period.

Competitive Analysis:

Key players in the global bio pharmabuffer market areAvantor, Alfa Aesar (Thermo Fisher), Merck, Lonza, Bio-Rad, BD, GE Healthcare, Promega Corporation, Hamilton Company, XZL BIO-TECHNOLOGY, SRL.Biopharm International, and among others.

Customization of the Report:This report can be customized to meet the client’s requirements. Please connect with our sales team (sales@fiormarkets.com), who will ensure that you get a report that suits your needs.